U.S. Infertility Drugs Market to Reach USD 2.28 Billion and Europe USD 2.22 Billion by 2035 as Gonadotropin Innovation, AI-Driven Personalization, and Expanding ART Access Drive Demand.

Austin, United States, Sept. 02, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Infertility Drugs Market was valued at USD 4.22 Billion in 2025 and is expected to reach USD 7.58 Billion by 2035, growing at a CAGR of 6.03% from 2026 to 2035. Demand is rising due to the rise in infertility cases in the world, reproductive awareness, and conducive government policies. Based on the data from WHO, about 48 million couples and 186 million people experience infertility in the world, and according to CDC statistics, 12% of the women between 15 to 44 years are experiencing infertility in the United States. The existence of 489 fertility clinics and ART centers in the U.S. is improving results.

New-generation gonadotropin products, injectable-oral combined treatments, and AI-aided individualized treatment approaches are helping in modernizing infertility treatment, whereas online pharmacies are making the distribution of fertility drugs more widespread through the integration of telemedicine.


Download the Infertility Drugs Market Sample Report: https://www.snsinsider.com/sample-request/6998

Infertility Drugs Market Key Highlights

  • Market size, 2025: USD 4.22 Billion
  • Market forecast, 2035: USD 7.58 Billion
  • CAGR: 6.03% from 2026 to 2035
  • Largest region: North America, approximately 39% share in 2025
  • Fastest-growing region: Asia Pacific, approximately 6.53% CAGR
  • Largest & fastest-growing drug class: Gonadotropins, approximately 39% share in 2025
  • Largest distribution channel: Hospital pharmacies, approximately 53% share in 2025
  • Fastest-growing distribution channel: Online pharmacies, approximately 6.63% CAGR
  • Largest route of administration: Oral, approximately 46.8% share in 2025
  • Fastest-growing route of administration: Transdermal/intranasal, approximately 7.4% CAGR
  • Largest & fastest-growing end user: Women, approximately 73% share in 2025

Market Relevance

Infertility treatment has gained importance in today’s reproductive health sector with an estimate from WHO that 48 million couples are affected around the globe along with 186 million people affected. Increased infertility cases reported by CDC in the age range of 15 to 44 years for the U.S. women which are around 12% along with increased number of ART clinics in the U.S., which have reached a figure of 489 clinics has greatly increased the need for medicines.

Infertility Drugs Market Overview

This market is made up of gonadotropins and other hormonal drug types that can be accessed through hospitals and internet pharmacies. These drugs are delivered through various modes such as oral, injection, transdermal, and intranasal. Recombinant FSH and hCG drugs continue to play an integral role in ovulation induction and hormonal therapy in assisted reproduction technology (ART) and IVF treatment cycles.

Strategic Market Outlook

Growth opportunities exist in personalized medicine that includes reproductive prediction via the use of artificial intelligence and recombinant hormones based on personalized protocols. The development of genomic tests until 2024 enhanced the success rate of preimplantation genetic testing by improving its accuracy and the expansion of public funding – especially 70% public funding of reproductive treatment costs in Japan and continued NHS coverage in the UK - expanded the target market.

The lack of insurance coverage and high cost of procedures are key limiting factors. On average, patients go through 2.5 treatment cycles before conceiving where each round of IVF costs from USD 15,000 to USD 30,000 and 19 US states provided insurance coverage for infertility treatment up to 2024.

Infertility Drugs Market Regional Analysis

North America held approximately 39% of the global market in 2025, making it the largest region, with the United States accounting for approximately 78% of regional revenue, supported by 489 ART centers nationwide and government regulation extending health insurance coverage for assisted reproductive technology and fertility hormone therapy.

The U.S. Infertility Drugs Market was valued at approximately USD 1.28 Billion in 2025 and is expected to reach approximately USD 2.28 Billion by 2035, growing at a CAGR of approximately 5.92%.

The Europe Infertility Drugs Market was worth USD 1.27 Billion in 2025 and is anticipated to reach USD 2.22 Billion by 2035, expanding at a CAGR of 5.80% from 2026 to 2035. Germany accounted for approximately 24% of European revenue in 2025, supported by government backing of biosimilar infertility treatment drugs and NHS coverage of fertility drugs in the UK.

The Asia-Pacific region is the fastest-growing region with a CAGR of approximately 6.53%, with China contributing approximately 37% of regional revenue in 2025. Japan finances 70% of fertility treatment costs, while India serves as a major producer of low-cost infertility treatment drugs.

Middle East & Africa: Saudi Arabia leads regional demand at approximately 26% of regional revenue in 2025.

Latin America: Brazil leads regional demand at approximately 36% of regional revenue in 2025.

Buy the Infertility Drugs Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/6998

Infertility Drugs Market Segment Analysis

By Drug Class: The Gonadotropins held nearly 39% of market share in 2025 with respect to recombinant FSH and hCG for ovulation induction and hormone therapy for ART and IVF procedures and this category of product is projected to grow at a faster rate.

By Distribution Channel: Hospital pharmacies have a share of 53% in the market as of 2025, due to the convenience of access and their associations with ART and fertility centers. Online pharmacies are growing at the fastest rate, with a CAGR of 6.63%.

By Route of Administration: The market share of oral administration was about 46.8% in 2025. The highest CAGR route was transdermal/intranasal route at around

By End-User: Women accounted for around 73% market share in 2025, reflecting that female infertility affects approximately 12% of U.S. women aged 15 to 44, and this segment is also expected to witness the fastest growth.

Infertility Drugs Market Key Trends

  • Development of next-generation gonadotropin formulations aimed at reducing ovarian hyperstimulation syndrome risk
  • Growing adoption of combination oral-injectable therapies to enhance ovarian stimulation and IVF success rates
  • Increasing use of artificial intelligence to personalize hormone therapy selection and predict reproductive outcomes
  • Expansion of online pharmacy distribution through telemedicine integration
  • Ongoing stem cell and regenerative medicine research targeting male reproductive disorders

Major key players include

  • Teva Pharmaceutical Industries Ltd.
  • Merck KGaA
  • Ferring B.V.
  • Bayer AG
  • Livzon Pharmaceutical Group Inc.
  • Mankind Pharma Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • IBSA Institut Biochimique SA
  • Organon & Co.
  • Fuji Pharma Co., Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Gedeon Richter Plc.
  • Besins Healthcare
  • Theramex
  • Laboratoire CCD
  • Genea Biomedx

Explore the Complete Infertility Drugs Market Report: https://www.snsinsider.com/reports/infertility-drugs-market-6998

CONTACT: About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: info@snsinsider.com